PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon
Inspira Technologies (NASDAQ: IINN) has enhanced its AI-driven medical platform by integrating a next-generation oxygenation indicator into its HYLA blood sensor technology. This advancement enables rapid detection of oxygen-related conditions without requiring blood draws, targeting the $2.5 billion Arterial Blood Gas analyzer market.
The HYLA system, currently under clinical evaluation at Sheba Medical Center, uses optical sensors and machine learning for real-time blood parameter monitoring. The company plans 510(k) FDA submissions in the second half of 2025. The technology complements their FDA-cleared INSPIRA ART100 system, which received its first U.S. purchase order through Glo-Med Networks in June 2024.
This development comes amid strong medtech M&A activity, with Q3 2024 seeing 275 deals worth $34 billion, a 35% increase year-over-year. The company is targeting both the blood gas analysis market and the $19 billion mechanical ventilation market, addressing the needs of approximately 20 million patients requiring mechanical ventilation globally.
Inspira Technologies (NASDAQ: IINN) ha migliorato la sua piattaforma medica basata sull'IA integrando un indicatore di ossigenazione di nuova generazione nella sua tecnologia di sensori per il sangue HYLA. Questo progresso consente una rapida rilevazione delle condizioni correlate all'ossigeno senza necessità di prelievo di sangue, puntando al mercato degli analizzatori di gas arterioso da 2.5 miliardi di dollari.
Il sistema HYLA, attualmente in fase di valutazione clinica presso il Sheba Medical Center, utilizza sensori ottici e apprendimento automatico per il monitoraggio in tempo reale dei parametri ematici. L'azienda prevede di presentare le domande 510(k) alla FDA nella seconda metà del 2025. La tecnologia completa il loro sistema INSPIRA ART100, approvato dalla FDA, che ha ricevuto il suo primo ordine d'acquisto negli Stati Uniti tramite Glo-Med Networks a giugno 2024.
Questo sviluppo si inserisce in un contesto di attività intensa di fusioni e acquisizioni nel settore med-tech, con il terzo trimestre del 2024 che ha registrato 275 affari per un valore di 34 miliardi di dollari, un incremento del 35% rispetto all'anno precedente. L'azienda punta sia al mercato dell'analisi dei gas ematici sia al mercato della ventilazione meccanica da 19 miliardi di dollari, rispondendo alle esigenze di circa 20 milioni di pazienti che necessitano di ventilazione meccanica a livello globale.
Inspira Technologies (NASDAQ: IINN) ha mejorado su plataforma médica impulsada por IA al integrar un indicador de oxigenación de próxima generación en su tecnología de sensores de sangre HYLA. Este avance permite la detección rápida de condiciones relacionadas con el oxígeno sin necesidad de extracciones de sangre, apuntando al mercado de analizadores de gases arteriales de 2.5 mil millones de dólares.
El sistema HYLA, actualmente en evaluación clínica en el Sheba Medical Center, utiliza sensores ópticos y aprendizaje automático para el monitoreo en tiempo real de los parámetros sanguíneos. La empresa planea enviar las solicitudes 510(k) a la FDA en la segunda mitad de 2025. La tecnología complementa su sistema INSPIRA ART100 aprobado por la FDA, que recibió su primer pedido de compra en EE. UU. a través de Glo-Med Networks en junio de 2024.
Este desarrollo ocurre en medio de una fuerte actividad de fusiones y adquisiciones en el sector medtech, con el tercer trimestre de 2024 viendo 275 acuerdos por un valor de 34 mil millones de dólares, un aumento del 35% en comparación con el año anterior. La empresa está apuntando tanto al mercado de análisis de gases en sangre como al mercado de ventilación mecánica de 19 mil millones de dólares, atendiendo las necesidades de aproximadamente 20 millones de pacientes que requieren ventilación mecánica a nivel mundial.
Inspira Technologies (NASDAQ: IINN)는 차세대 산소 지표를 HYLA 혈액 센서 기술에 통합하여 AI 기반의 의료 플랫폼을 개선했습니다. 이러한 발전은 혈액 채취 없이도 산소 관련 상태를 신속하게 감지할 수 있게 하며, 25억 달러 규모의 동맥혈가스 분석기 시장을 목표로 하고 있습니다.
현재 Sheba Medical Center에서 임상 평가 중인 HYLA 시스템은 광학 센서와 머신 러닝을 사용하여 실시간으로 혈액 매개 변수를 모니터링합니다. 회사는 2025년 하반기 중으로 510(k) FDA 제출을 계획하고 있습니다. 이 기술은 FDA 승인을 받은 INSPIRA ART100 시스템을 보완하며, 이 시스템은 2024년 6월 Glo-Med Networks를 통해 미국에서 첫 번째 구매 주문을 받았습니다.
이번 발전은 강력한 의료 기술 M&A 활동 속에서 이루어지며, 2024년 3분기에는 275건의 거래가 340억 달러에 달하며, 전년 대비 35% 증가했습니다. 회사는 혈액 가스 분석 시장과 190억 달러 규모의 기계적 환기 시장을 목표로 하고 있으며, 전 세계 약 2000만 명의 기계적 환기를 필요로 하는 환자의 요구를 해결하고 있습니다.
Inspira Technologies (NASDAQ: IINN) a amélioré sa plateforme médicale basée sur l'IA en intégrant un indicateur d'oxygénation de nouvelle génération dans sa technologie de capteurs sanguins HYLA. Cette avancée permet une détection rapide des conditions liées à l'oxygène sans nécessiter de prélèvements sanguins, ciblant le marché des analyseurs de gaz artériel d'une valeur de 2,5 milliards de dollars.
Le système HYLA, actuellement évalué cliniquement au Sheba Medical Center, utilise des capteurs optiques et de l'apprentissage automatique pour le suivi en temps réel des paramètres sanguins. L'entreprise prévoit de soumettre des demandes 510(k) à la FDA dans la seconde moitié de 2025. La technologie complète leur système INSPIRA ART100, qui a été approuvé par la FDA et a reçu sa première commande d'achat aux États-Unis par le biais de Glo-Med Networks en juin 2024.
Ce développement s'inscrit dans un contexte d'activités intenses de fusions et d'acquisitions dans le secteur medtech, avec un 3ème trimestre 2024 ayant enregistré 275 transactions d'une valeur de 34 milliards de dollars, soit une augmentation de 35 % par rapport à l'année précédente. L'entreprise vise à la fois le marché de l'analyse des gaz sanguins et le marché de la ventilation mécanique d'une valeur de 19 milliards de dollars, répondant aux besoins d'environ 20 millions de patients nécessitant une ventilation mécanique dans le monde.
Inspira Technologies (NASDAQ: IINN) hat seine KI-gestützte medizinische Plattform verbessert, indem es einen Sauerstoffindikator der nächsten Generation in seine HYLA-Blutsensortechnologie integriert hat. Dieser Fortschritt ermöglicht eine schnelle Erkennung von sauerstoffbezogenen Zuständen, ohne dass Blutabnahmen erforderlich sind und zielt auf den Markt für arterielle Blutgasanalysegeräte im Wert von 2,5 Milliarden Dollar.
Das HYLA-System, das sich derzeit in klinischer Erprobung am Sheba Medical Center befindet, nutzt optische Sensoren und maschinelles Lernen zur Echtzeitüberwachung von Blutparametern. Das Unternehmen plant, im zweiten Halbjahr 2025 510(k)-Anträge bei der FDA einzureichen. Die Technologie ergänzt ihr von der FDA zugelassenes INSPIRA ART100-System, das im Juni 2024 seine erste Kaufbestellung in den USA über Glo-Med Networks erhalten hat.
Diese Entwicklung findet vor dem Hintergrund einer intensiven M&A-Aktivität im Medizintechniksektor statt, wobei das dritte Quartal 2024 275 Transaktionen im Wert von 34 Milliarden Dollar verzeichnete, was einem Anstieg von 35 % im Vergleich zum Vorjahr entspricht. Das Unternehmen zielt sowohl auf den Markt für Blutgasanalyse als auch auf den Markt für mechanische Belüftung im Wert von 19 Milliarden Dollar ab und adressiert die Bedürfnisse von rund 20 Millionen Patienten, die weltweit eine mechanische Belüftung benötigen.
- None.
- None.
Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth
The HYLA System: A New Paradigm in Blood Monitoring, powered by AI
The enhanced HYLA blood sensor system leverages sophisticated optical sensors and machine learning algorithms to provide real-time monitoring of vital blood parameters. This AI-powered technology is designed to detect and alert healthcare providers to changes in tissue oxygenation and early warning signs of respiratory complications, including hypoxia.
Currently undergoing clinical evaluation at Sheba Medical Center, ranked among the world's top 10 smartest hospitals by Newsweek, the system targets what the companies notes as the
Notably, the product is intended for dual use – both as a standalone product, as well as an addon to Inspira’s ART100 system, which is already in commercialization phases after reviewing FDA clearance. The ART100 is designed to revolutionize extracorporeal blood circulation by integrating cutting-edge technology with intuitive design to optimize patient care during crucial times. As such, this enhancement of the HYLA also strengthens Inspira’s offering also in what the companies says is a
Expansive Product line with FDA Cleared Products being Deployed
While HYLA advances through clinical evaluation, Inspira has already achieved significant business milestones with its INSPIRA ART100 system. Following FDA 510(k) clearance in May 2024 for Cardiopulmonary Bypass procedures and subsequent Israeli AMAR certification, the company secured its first
Inspira's technology ecosystem extends beyond blood monitoring to address critical challenges in respiratory care. The company's proprietary VORTX technology represents a novel approach to blood oxygenation, designed to minimize blood trauma compared to traditional fiber membrane technologies. This innovation supports their flagship INSPIRA ART (Gen 2) system, which targets the
Market Context and Importance
Inspira's technological advances is particularly relevant given current healthcare challenges. With approximately 20 million patients annually requiring mechanical ventilation globally and mortality rates exceeding
From a financial perspective, deal activity in medical technology presents a compelling backdrop for innovative AI-focused companies like Inspira. Overall medical device M&A showed robust growth in Q3 2024, with GlobalData reporting 275 deals worth
What to look out for
Several key developments seem to be expected in the coming months, including the deployment of INSPIRA ART100 systems in leading
Click here to Subscribe for more updates like this
Latest News from Inspira:
- Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support
-
Inspira™ Technologies Prepares its First Life-Support Systems for Deployment at a Leading
U.S. Hospital - Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by PESG Research, a brand affiliated with the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205235418/en/
PESG Editorial Desk
ronald@futuremarketsresearch.com
Source: PESG
FAQ
What are the key features of Inspira's enhanced HYLA blood sensor technology?
When is Inspira Technologies (IINN) planning to submit its HYLA system for FDA approval?
What is the market size potential for Inspira's HYLA and ART100 systems?
Where is the HYLA blood sensor currently being clinically evaluated?
What recent milestones has IINN achieved with its ART100 system?
How does the current medtech M&A environment impact IINN's market position?
